康乃德生物医药(CNTB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CNTB 康乃德生物医药

已收盘 09-28 16:00:00 EDT

1.08

+0.00

0.00%

盘后1.11

+0.03+2.77%

19:48 EDT

最高1.11	最低1.05	成交量246.44万
今开1.08	昨收1.08	日振幅5.56%
总市值6,800万	流通市值2,331万	总股本6,296万
成交额266.34万	换手率11.42%	流通股本2,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CNTB","market":"US","secType":"STK","nameCN":"康乃德生物医药","latestPrice":1.08,"timestamp":1790625600000,"preClose":1.08,"halted":0,"volume":2464393,"hourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.08,"latestTime":"19:48 EDT","volume":1482876,"amount":1601667.7216,"timestamp":1790639313392,"change":0.0299,"changeRate":0.027685,"amplitude":0.027778},"delay":0,"changeRate":0,"floatShares":21582500,"shares":62963853,"eps":-1.193347,"marketStatus":"已收盘","change":0,"latestTime":"09-28 16:00:00 EDT","open":1.08,"high":1.11,"low":1.05,"amount":2663423.5396625004,"amplitude":0.055556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.193347,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790668800000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1616126400000,"exchange":"NASDAQ","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.09,"preClose":1.08,"latestTime":"09:29 EDT","volume":9604,"amount":10351.8135392,"timestamp":1790602170066,"change":0.01,"changeRate":0.009259,"amplitude":0.064815},"postHourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.08,"latestTime":"19:48 EDT","volume":1482876,"amount":1601667.7216,"timestamp":1790639313392,"change":0.0299,"changeRate":0.027685,"amplitude":0.027778},"volumeRatio":2.211549,"impliedVol":2.7889,"impliedVolPercentile":0.9442},"requestUrl":"/m/hq/s/CNTB","defaultTab":"news","newsList":[{"id":"1153083148","title":"康乃德生物医药：Rademikibart在哮喘患者中展现良好耐受性与低不良事件发生率","url":"https://stock-news.laohu8.com/highlight/detail?id=1153083148","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153083148?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:08","pubTimestamp":1789470534,"startTime":"0","endTime":"0","summary":"在哮喘治疗领域，康乃德生物医药传来令人振奋的消息——其研发的药物Rademikibart展现出卓越的安全性特征。这一候选药物在患者群体中表现出良好的耐受性，同时不良反应的发生率维持在较低水平，为饱受哮喘困扰的患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183435314","title":"康乃德生物医药：Rademikibart在第7天展现统计学显著肺功能改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1183435314","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183435314?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:08","pubTimestamp":1789470533,"startTime":"0","endTime":"0","summary":"康乃德生物医药（Connect Biopharma）近日披露，其候选药物Rademikibart在临床试验中展现出令人瞩目的积极信号。数据显示，与安慰剂对照组相比，接受该药物治疗的患者在用药后仅第7天便实现了肺功能的显著提升——这一差异在统计学上具有明确意义。此结果为该药物在呼吸系统疾病治疗领域的潜力增添了有力佐证，同时也为后续研发进程注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195209241","title":"康乃德生物医药公布Rademikibart全球II期研究积极初步顶线数据：作为成人与青少年哮喘合并2型炎症患者急性加重期的附加治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1195209241","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195209241?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:01","pubTimestamp":1789470075,"startTime":"0","endTime":"0","summary":"康乃德生物医药今日宣布，其评估Rademikibart作为附加治疗药物、用于成人和青少年哮喘合并2型炎症患者急性加重期的全球II期研究，已取得令人振奋的初步顶线数据。这项备受瞩目的临床试验，旨在探究Rademikibart在缓解急性哮喘发作方面的潜力与安全性。Rademikibart若能成功研发上市，有望填补当前治疗策略中的重要空白，为患者提供更为精准和有效的干预手段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192576644","title":"奥本海默首予康乃德生物医药“跑赢大盘”评级，目标价8美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192576644","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192576644?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:27","pubTimestamp":1783600039,"startTime":"0","endTime":"0","summary":"投资机构奥本海默近日发布研报，首次将康乃德生物医药纳入研究覆盖范围，并给予其“跑赢大盘”的积极评级。该机构为这家生物技术公司设定的目标股价为每股8美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126934188","title":"Piper Sandler首予康乃德生物医药“增持”评级，目标价7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126934188","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126934188?lang=zh_cn&edition=full","pubTime":"2026-06-26 15:40","pubTimestamp":1782459617,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler近日发布研究报告，首次覆盖康乃德生物医药，并给予其股票“增持”评级，同时设定7美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131513063","title":"康乃德生物医药宣布完成评估雷迪米基巴治疗哮喘急性发作的II期海风研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1131513063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131513063?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:01","pubTimestamp":1781701278,"startTime":"0","endTime":"0","summary":"康乃德生物医药（Connect Biopharma Holdings Ltd.）已宣布其II期“海风”（Seabreeze）研究完成患者入组。该研究旨在评估其候选药物雷迪米基巴（rademikibart）用于治疗哮喘急性发作的疗效与安全性。这项关键性试验的推进，标志着公司在探索呼吸系统疾病创新疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198980770","title":"康乃德生物医药控股有限公司 - 计划转售至多610万股普通股 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1198980770","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198980770?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:34","pubTimestamp":1778848459,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的文件，康乃德生物医药控股有限公司（Connect Biopharma Holdings Ltd.）计划进行一项普通股转售。文件显示，此次拟议的转售涉及高达610万股公司普通股。\n这一行动通常意味着现有股东，例如早期投资者或公司内部人士，可能计划在公开市场上出售其持有的部分股份。此类转售备案是资本市场中的常规操作，旨在提前向市场披露潜在的股票供应增加，确保信息的透明性。投资者通常会关注此类动向，以评估其对公司股价可能产生的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114135897","title":"康乃德生物医药：两项Seabreeze Stat研究顶线结果预计年中公布，目前进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=1114135897","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114135897?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:13","pubTimestamp":1778591604,"startTime":"0","endTime":"0","summary":"康乃德生物医药目前进展顺利，预计仍将按计划于今年年中公布其两项Seabreeze Stat研究的关键顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108235284","title":"康乃德生物医药：数据监测委员会报告Seabreeze Stat研究无安全隐患或治疗相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1108235284","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108235284?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:10","pubTimestamp":1776949846,"startTime":"0","endTime":"0","summary":"康乃德生物医药控股有限公司宣布，其独立数据监测委员会针对Seabreeze Stat临床研究项目完成最新安全评估。评估结果显示，试验中未发现任何值得关注的安全性问题，也未出现与治疗方案相关的严重不良事件报告。这一积极进展为候选药物的后续研发进程提供了重要的安全性数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174518832","title":"康乃德生物医药：预设定中期分析后，Seabreeze二期研究将按计划继续推进患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1174518832","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174518832?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:09","pubTimestamp":1776949756,"startTime":"0","endTime":"0","summary":"康乃德生物医药控股有限公司宣布，其Seabreeze二期临床试验在完成预设的中期分析后，决定按原定方案持续推进患者招募工作。此项分析旨在评估研究的有效性与安全性参数，结果表明当前试验进展符合预期轨迹，支持继续开展后续研究阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167678957","title":"康乃德生物医药宣布完成2020万美元私募融资 资金储备将支撑运营至2027年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1167678957","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167678957?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:05","pubTimestamp":1774868718,"startTime":"0","endTime":"0","summary":"临床阶段生物制药企业康乃德生物医药近日与特定机构投资者达成证券购买协议，通过非公开配售发行613万股普通股，每股定价3.25美元。此次融资由现有最大投资方帕纳西亚创投领投，并吸引多家美国医疗健康领域新老投资者参与。本次私募预计募集总额约2020万美元，交易预计于2026年3月31日左右完成。结合现有现金及短期投资，本轮融资将使公司运营资金储备延续至2027年下半年。公司承诺在交易完成45天内向美国证交会提交转售股份登记声明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198277618","title":"康乃德生物医药Rademikibart在长达52周的特应性皮炎3期研究中展现快速且持久的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1198277618","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198277618?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:05","pubTimestamp":1774868713,"startTime":"0","endTime":"0","summary":"康乃德生物医药宣布，其核心候选药物Rademikibart在针对中重度特应性皮炎患者开展的3期临床研究中，展现出快速起效且持久的治疗效果，疗效数据持续至第52周。\n研究结果显示，Rademikibart能够显著改善患者的皮损严重程度和瘙痒症状。其疗效在治疗初期便迅速显现，并在此后长达一年的观察期内得以稳定维持，凸显了该药物在长期疾病管理中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174454518","title":"康乃德生物医药公布静脉注射Rademikibart针对哮喘或慢阻肺患者一期研究的积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1174454518","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174454518?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:02","pubTimestamp":1774868539,"startTime":"0","endTime":"0","summary":"康乃德生物医药宣布，其静脉注射（IV）Rademikibart在哮喘或慢性阻塞性肺疾病（COPD）患者中进行的1期研究获得了积极的顶线数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139187190","title":"康乃德生物医药Rademikibart 300毫克静脉推注在哮喘与慢阻肺治疗中实现FEV1快速改善≥200毫升","url":"https://stock-news.laohu8.com/highlight/detail?id=1139187190","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139187190?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868484,"startTime":"0","endTime":"0","summary":"康乃德生物医药宣布，其研发的Rademikibart 300毫克静脉推注剂型在针对哮喘及慢性阻塞性肺病的临床研究中取得突破性进展。数据显示，该治疗方案能够促使患者第一秒用力呼气容积实现快速且显著的提升，改善幅度达到或超过200毫升。这一结果凸显了Rademikibart在呼吸系统疾病治疗领域的潜在价值。康乃德生物医药将继续推进相关临床研究，深入探索Rademikibart的疗效与安全性，致力于为全球呼吸疾病患者带来更优的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186382748","title":"康乃德生物医药Rademikibart耐受性良好，未出现严重或重度不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1186382748","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186382748?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868477,"startTime":"0","endTime":"0","summary":"康乃德生物医药控股有限公司公布的最新数据显示，其核心候选药物Rademikibart在临床试验中表现出良好的耐受性。研究期间未报告任何严重或重度不良事件，这一结果进一步支持了该药物的安全性特征。Rademikibart作为一种新型治疗性抗体，目前正针对多种免疫介导性疾病开展临床研究。此次积极的安全性数据为其后续开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120708929","title":"康乃德生物医药Seabreeze Stat二期研究持续招募受试者，顶线数据预计2026年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1120708929","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120708929?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868473,"startTime":"0","endTime":"0","summary":"康乃德生物医药控股有限公司宣布，其针对Seabreeze Stat的二期临床研究目前正在进行患者招募工作。该项研究的关键顶线数据结果预计将于2026年中期获得。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518279704","title":"康乃德生物盘中异动 早盘快速跳水5.88%报0.800美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518279704?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:15","pubTimestamp":1741619739,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时15分，康乃德生物股票出现异动，股价快速下挫5.88%。截至发稿，该股报0.800美元/股，成交量3951股，换手率0.01%，振幅3.53%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康乃德生物股票所在的生物技术行业中，整体涨幅为0.76%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031023153998a2b5b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031023153998a2b5b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517848161","title":"康乃德生物盘中异动 股价大跌5.68%报0.830美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517848161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517848161?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:12","pubTimestamp":1741273951,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时12分，康乃德生物股票出现异动，股价快速下挫5.68%。截至发稿，该股报0.830美元/股，成交量1691股，换手率0.00%，振幅0.00%。康乃德生物股票所在的生物技术行业中，整体跌幅为0.32%。其相关个股中，Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Plus Therapeutics, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1506.68%、827.09%、75.14%，振幅较大的相关个股有Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Moolec Science Sa C/Wts ，振幅分别为48.42%、44.64%、44.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231231abeb827f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231231abeb827f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517894669","title":"康乃德生物盘中异动 早盘股价大涨10.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517894669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517894669?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:36","pubTimestamp":1741188983,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时36分，康乃德生物股票出现异动，股价快速上涨10.27%。截至发稿，该股报0.905美元/股，成交量2326股，换手率0.00%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康乃德生物股票所在的生物技术行业中，整体涨幅为1.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233623abe9c593&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233623abe9c593&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516608274","title":"康乃德生物盘中异动 早盘股价大跌8.33%报0.800美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516608274?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:07","pubTimestamp":1741100876,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时07分，康乃德生物股票出现异动，股价急速跳水8.33%。截至发稿，该股报0.800美元/股，成交量297股，换手率0.00%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康乃德生物股票所在的生物技术行业中，整体涨幅为0.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030423075696394f6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030423075696394f6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.connectbiopharm.com","stockEarnings":[{"period":"1week","weight":-0.1562},{"period":"1month","weight":-0.5365},{"period":"3month","weight":-0.5068},{"period":"6month","weight":-0.687},{"period":"1year","weight":-0.3609},{"period":"ytd","weight":-0.617}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"康乃德生物制药控股有限公司于2015年11月23日在开曼群岛注册成立。该公司是一家临床阶段的生物制药公司，致力于改变哮喘和慢性阻塞性肺疾病（“COPD”）的护理方式。该公司正在推进rademikibart，这是一种下一代可能是同类中最好的抗体，旨在靶向白细胞介素-4受体α（“IL-4Rα”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.028496},{"month":2,"riseRate":0.6,"avgChangeRate":-0.025044},{"month":3,"riseRate":0.4,"avgChangeRate":-0.062942},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.024639},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.059238},{"month":6,"riseRate":0.666667,"avgChangeRate":0.069047},{"month":7,"riseRate":0.333333,"avgChangeRate":0.10035},{"month":8,"riseRate":0.833333,"avgChangeRate":0.185246},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.155094},{"month":10,"riseRate":0.4,"avgChangeRate":0.007717},{"month":11,"riseRate":0.2,"avgChangeRate":-0.108453},{"month":12,"riseRate":1,"avgChangeRate":0.142382}],"exchange":"NASDAQ","name":"康乃德生物医药","nameEN":"Connect Biopharma Holdings Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康乃德生物医药(CNTB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康乃德生物医药(CNTB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康乃德生物医药,CNTB,康乃德生物医药股票,康乃德生物医药股票老虎,康乃德生物医药股票老虎国际,康乃德生物医药行情,康乃德生物医药股票行情,康乃德生物医药股价,康乃德生物医药股市,康乃德生物医药股票价格,康乃德生物医药股票交易,康乃德生物医药股票购买,康乃德生物医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康乃德生物医药(CNTB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康乃德生物医药(CNTB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}